Equities Analysts Set Expectations for Soligenix Q3 Earnings

Soligenix Inc. (NASDAQ:SNGX) – Equities researchers at Zacks Small Cap upped their Q3 2025 EPS estimates for Soligenix in a report issued on Tuesday, September 30th. Zacks Small Cap analyst D. Bautz now anticipates that the biopharmaceutical company will post earnings per share of ($0.63) for the quarter, up from their prior estimate of ($0.82). The consensus estimate for Soligenix’s current full-year earnings is ($4.65) per share. Zacks Small Cap also issued estimates for Soligenix’s Q4 2025 earnings at ($0.61) EPS, FY2025 earnings at ($3.02) EPS, FY2026 earnings at ($1.68) EPS and FY2027 earnings at ($1.50) EPS.

A number of other brokerages have also weighed in on SNGX. Wall Street Zen lowered shares of Soligenix to a “strong sell” rating in a report on Saturday, August 16th. Alliance Global Partners decreased their price target on shares of Soligenix from $10.00 to $6.00 and set a “buy” rating on the stock in a report on Wednesday, July 16th. One analyst has rated the stock with a Buy rating, Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $6.00.

Soligenix Stock Up 3.2%

Shares of SNGX opened at $1.28 on Friday. The firm has a market cap of $5.49 million, a PE ratio of -0.34 and a beta of 1.96. The company’s fifty day moving average is $2.61 and its two-hundred day moving average is $2.09. Soligenix has a fifty-two week low of $1.09 and a fifty-two week high of $6.23.

Soligenix (NASDAQ:SNGX) last announced its earnings results on Thursday, August 14th. The biopharmaceutical company reported ($0.82) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.79) by ($0.03).

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Soligenix stock. Connective Capital Management LLC lifted its stake in Soligenix Inc. (NASDAQ:SNGX) by 17.6% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 119,481 shares of the biopharmaceutical company’s stock after buying an additional 17,848 shares during the period. Connective Capital Management LLC owned approximately 3.67% of Soligenix worth $157,000 as of its most recent SEC filing. 3.60% of the stock is currently owned by institutional investors.

Soligenix Company Profile

Soligenix, Inc, a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease.